indazoles has been researched along with Parkinson Disease in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 10 (41.67) | 24.3611 |
| 2020's | 7 (29.17) | 2.80 |
| Authors | Studies |
|---|---|
| Alessi, DR; Ganley, IG; Reith, AD; Singh, F; Tasegian, A | 1 |
| Aoyama, E; Dansithong, W; Dexheimer, T; Gandelman, M; Henderson, MJ; Huynh, DP; Jadhav, A; Kales, SC; Maag, G; Paul, S; Pulst, SM; Rai, G; Scoles, DR; Simeonov, A; Sun, H; Whitehill, BM; Zakharov, A | 1 |
| Fitch, WL; Gajera, CR; Lam, G; Leśniak, RK; Montine, TJ; Nguyen, KC; Nichols, RJ; Schonemann, M; Smith, M; Zhao, J | 1 |
| Pal, D; Sahu, P | 1 |
| Algar, S; Ballesteros, JA; Benhamú, B; Brea, J; Cincilla, G; García-Cárceles, J; Ladron de Guevara-Miranda, D; López-Rodríguez, ML; Loza, MI; Roberts, RS; Rodríguez de Fonseca, F; Sánchez-Martínez, M; Sánchez-Merino, A; Teresa de Los Frailes, M; Vázquez-Villa, H | 1 |
| Acton, JJ; Ardolino, MJ; Bennett, DJ; Candito, DA; Chau, RW; Ciaccio, P; DeMong, DE; DiMauro, EF; Ellis, JM; Faltus, R; Fell, MJ; Fuller, PH; Graham, TH; Gulati, A; Gunaydin, H; Hegde, LG; Kattar, S; Kennedy, ME; Keylor, MH; Kurukulasuriya, R; Lapointe, BT; Lesburg, CA; Liu, P; Liu, W; Maddess, ML; Martinot, TA; McMinn, SE; Methot, JL; Minnihan, EC; Morriello, GJ; Moy, LY; Neelamkavil, S; Nogle, L; Otte, KM; Palte, RL; Piesvaux, JA; Pio, B; Scott, JD; Simov, V; Su, J; Tong, L; Wood, HB; Woodhouse, JD; Xiong, T; Yan, X; Yu, H | 1 |
| Krainc, D; Merchant, K; Nguyen, M; Schwake, M; Severino, A; Young, TJ; Ysselstein, D | 1 |
| Cookson, MR; Kluss, JH; Lewis, PA; Li, Y; Mamais, A; Manzoni, C; Mazza, MC | 1 |
| Atashrazm, F; Bolliger, MF; Dzamko, N; Halliday, GM; Hammond, D; Lewis, SJG; Matar, E; Nichols, RJ; Perera, G; Schüle, B | 1 |
| Brown, H; Henderson, MX; Lee, VMY; McGeary, I; Olufemi, MF; Sengupta, M; Trojanowski, JQ; Zhang, B | 1 |
| Del-Bel, EA; Espadas, I; Moratalla, R; Solís, O | 1 |
| Bortolanza, M; Cavalcanti-Kiwiatkoski, R; da-Silva, CA; Del-Bel, E; Mitkovski, M; Padovan-Neto, FE; Raisman-Vozari, R | 1 |
| Kumar, JB; Kumari, R; Luthra, PM | 1 |
| Basu, K; Cheewatrakoolpong, B; DeMong, DE; Ellis, JM; Fell, MJ; Hyde, LA; Kennedy, ME; Lin, Y; Markgraf, CG; Mei, H; Miller, M; Mirescu, C; Morrow, JA; Parker, EM; Poulet, FM; Scott, JD; Smith, MD; Yin, Z; Zhou, X | 1 |
| Bariotto-Dos-Santos, KD; Bortolanza, M; da-Silva, CA; Del-Bel, E; Dos-Santos-Pereira, M | 1 |
| Chong-Fa, L; Jin-Jun, R; Lu, Z; Wen-Ting, Z; Wen-Ya, W; Xiao-Feng, L; Yuan-Yuan, X | 1 |
| Agnihotri, G; Baptista, MA; Basu, K; Bilodeau, MT; Chang, RK; Columbus, J; Dai, X; DeMong, DE; Drolet, RE; Embrey, MW; Fell, MJ; Greshock, TJ; Harris, J; Hruza, A; Hu, Z; Hyde, LA; Kennedy, ME; Kern, JT; Kuvelkar, R; Li, SW; Lin, SI; Lin, Y; Liu, H; Macala, MK; McCauley, JA; Mei, H; Miller, MW; Mirescu, C; Morrow, JA; Nargund, R; Parker, EM; Poirier, M; Renger, JJ; Sanders, JM; Scott, JD; Shi, ZC; Stamford, AW; Sur, SM; Tiscia, HE; Walsh, P; Xiao, L; Yin, Z; Zhang, H; Zhang, X; Zhou, X | 1 |
| Benigno, A; Crescimanno, G; Di Giovanni, G; Di Matteo, V; Esposito, E; Pierucci, M | 1 |
| Del-Bel, EA; Echeverry, MB; Padovan-Neto, FE; Tumas, V | 1 |
| Benigno, A; Crescimanno, G; Di Giovanni, G; Di Matteo, V; Esposito, E; Giuliano, DA; Pierucci, M | 1 |
| Flumerfelt, BA; Hrycyshyn, AW; Rajakumar, B; Rajakumar, N | 1 |
| Dunbar, GL; Haik, KL; Hargrove, C; Mazei-Robison, M; Patton, J; Sandstrom, MI; Shear, DA | 1 |
| Dawson, TM; Dawson, VL; Jackson-Lewis, V; Przedborski, S; Shibata, T; Yokoyama, R | 1 |
| Snyder, SH | 1 |
1 review(s) available for indazoles and Parkinson Disease
| Article | Year |
|---|---|
Importance of Indazole against Neurological Disorders.
Topics: Glycogen Synthase Kinase 3; Humans; Indazoles; Monoamine Oxidase; Nervous System Diseases; Parkinson Disease; Structure-Activity Relationship | 2022 |
23 other study(ies) available for indazoles and Parkinson Disease
| Article | Year |
|---|---|
Impact of Type II LRRK2 inhibitors on signaling and mitophagy.
Topics: Animals; Benzamides; Fibroblasts; Gene Knockout Techniques; HEK293 Cells; HeLa Cells; Humans; Imidazoles; Indazoles; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice; Mice, Inbred C57BL; Mitophagy; Neutrophils; Parkinson Disease; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrimidines; Quinolines; Signal Transduction; Transfection | 2021 |
The AKT modulator A-443654 reduces α-synuclein expression and normalizes ER stress and autophagy.
Topics: alpha-Synuclein; Autophagy; Endoplasmic Reticulum Stress; Gene Expression Regulation; HEK293 Cells; Humans; Indazoles; Indoles; Parkinson Disease; Proto-Oncogene Proteins c-akt | 2021 |
Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.
Topics: Animals; Brain; Disease Models, Animal; Drug Discovery; Humans; Indazoles; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Lung; Male; Mice; Molecular Docking Simulation; Mutation; Neuroprotective Agents; Parkinson Disease; Phenotype; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Rodentia; Structure-Activity Relationship | 2022 |
2-(Fluoromethoxy)-4'-(
Topics: Animals; Biphenyl Compounds; Cocaine; Dopamine; Dopamine Agents; Dopamine Agonists; Humans; Indazoles; Levodopa; Ligands; Mice; Nitrofurans; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D1 | 2022 |
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1
Topics: Adenosine Triphosphate; Animals; Brain; Humans; Indazoles; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Leukocytes, Mononuclear; Parkinson Disease; Protein Kinase Inhibitors; Rats | 2022 |
LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.
Topics: alpha-Synuclein; Cells, Cultured; Dopamine; Dopaminergic Neurons; Glucosylceramidase; Humans; Indazoles; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Lysosomes; Mutation, Missense; Parkinson Disease; Pyrimidines; RNA Interference | 2019 |
Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo.
Topics: Animals; Brain; Drug Evaluation, Preclinical; Endosomes; Gain of Function Mutation; Gene Knock-In Techniques; Humans; Indazoles; Kidney; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Lung; Lysosomes; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mitochondrial Proteins; Organ Specificity; Parkinson Disease; Phosphorylation; Point Mutation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proteome; Pyrimidines; rab GTP-Binding Proteins; Random Allocation | 2021 |
LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Female; Humans; Indazoles; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Leukocytes, Mononuclear; Male; Middle Aged; Neutrophils; Parkinson Disease; Phosphorylation; Pyrimidines; rab GTP-Binding Proteins | 2019 |
LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice.
Topics: alpha-Synuclein; Animals; Cell Death; Hand Strength; Indazoles; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice; Mice, Inbred C57BL; Neurons; Parkinson Disease; Pyrimidines | 2019 |
Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
Topics: Animals; Antiparkinson Agents; Benserazide; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Gene Expression Regulation; Homeodomain Proteins; Indazoles; Levodopa; Mice; Mice, Knockout; Molsidomine; Nitric Oxide Donors; Parkinson Disease; Signal Transduction; Time Factors; Transcription Factors | 2015 |
Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Indazoles; Inflammation; Levodopa; Male; Neuroglia; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Parkinson Disease; Rats; Rats, Wistar; Up-Regulation | 2015 |
Post-lesion administration of 7-NI attenuated motor and non-motor deficits in 6-OHDA induced bilaterally lesioned female rat model of Parkinson's disease.
Topics: Animals; Brain; Catalase; Dopamine; Female; Glutathione; Indazoles; Lipid Peroxidation; Motor Skills; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats, Sprague-Dawley; Superoxide Dismutase | 2015 |
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
Topics: Alveolar Epithelial Cells; Animals; Antiparkinson Agents; Behavior, Animal; Binding, Competitive; Brain; Brain Chemistry; Cell Line; Cerebral Cortex; Dose-Response Relationship, Drug; Humans; Indazoles; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Lung; Male; Mice; Mice, Inbred C57BL; Mutation; Parkinson Disease; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines | 2015 |
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
Topics: Amantadine; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Indazoles; Levodopa; Male; Medial Forebrain Bundle; Microinjections; Nitroprusside; Oxidopamine; Parkinson Disease; Rats | 2016 |
Protective role of 6-Hydroxy-1-H-Indazole in an MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Indazoles; Male; Mesencephalon; Mice; Neostriatum; Parkinson Disease; Phosphorylation; Substantia Nigra; tau Proteins; Tyrosine 3-Monooxygenase | 2016 |
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
Topics: Animals; Brain; Enzyme Inhibitors; Humans; Indazoles; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Molecular Docking Simulation; Parkinson Disease; Rats; Rats, Wistar | 2017 |
Involvement of nitric oxide in nigrostriatal dopaminergic system degeneration: a neurochemical study .
Topics: Animals; Corpus Striatum; Indazoles; Male; Molsidomine; Nitric Oxide; Nitric Oxide Donors; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2009 |
Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Motor Activity; Nitric Oxide Synthase; Nitroarginine; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra | 2009 |
7-nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: an in vivo microdialysis study.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Disease Models, Animal; Dopamine; Enzyme Inhibitors; Indazoles; Male; Microdialysis; Neurons; Neuroprotective Agents; Nitric Oxide Synthase Type I; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2006 |
Nitric oxide-containing neurons in long-term grafts in a rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Choline; Disease Models, Animal; Female; Indazoles; Methamphetamine; NADPH Dehydrogenase; Neostriatum; Neurons; Nitric Oxide; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Pregnancy; Rats; Rats, Sprague-Dawley; Rotation; Somatostatin; Time Factors; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2007 |
7-nitroindazole attenuates 6-hydroxydopamine-induced spatial learning deficits and dopamine neuron loss in a presymptomatic animal model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Dopamine; Indazoles; Learning Disabilities; Male; Maze Learning; NADP; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Spatial Behavior; Substantia Nigra | 2008 |
Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cerebellum; Corpus Striatum; Dopamine; Dopamine Agents; Enzyme Inhibitors; Homovanillic Acid; Humans; Indazoles; Isoenzymes; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; MPTP Poisoning; Nerve Degeneration; Neurons; Nitric Oxide; Nitric Oxide Synthase; Parkinson Disease; Substantia Nigra | 1996 |
No NO prevents parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Enzyme Inhibitors; Humans; Indazoles; Neurons; Nitric Oxide; Nitric Oxide Synthase; Papio; Parkinson Disease | 1996 |